Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Sunitinib Stories

2012-11-27 08:21:55

-- First publication of the global Phase III CORRECT and GRID study data of the oral multi-kinase inhibitor regorafenib TORONTO, Nov. 27, 2012 /CNW/ - Bayer HealthCare today announced that the results of two pivotal Phase III studies for regorafenib were published online in the journal The Lancet ahead of a future print publication. Data from the CORRECT (Metastatic Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) and GRID...

2012-11-23 10:50:21

A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial. The treatment of gastrointestinal stromal tumor, or GIST, even in its advanced metastatic stage, has been dramatically improved with two oral targeted drugs — imatinib (Gleevec) and...

2012-11-08 04:22:53

TUEBINGEN, Germany, November 8, 2012 /PRNewswire/ -- immatics biotechnologies GmbH, a biopharmaceutical company developing rationally designed therapeutic vaccines that are active against cancer, announced today that it has completed patient recruitment into the pivotal phase 3 trial evaluating its lead cancer vaccine IMA901 for renal cell carcinoma (RCC). The trial has completed patient inclusion and it is expected that around 345 patients will be randomized across 10 countries...

2012-08-30 06:25:21

WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., Aug. 30, 2012 /PRNewswire/ -- Bayer HealthCare and Onyx Pharmaceuticals (NASDAQ: ONXX) today announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment. Regorafenib is a...

2012-07-29 06:20:09

TUEBINGEN, Germany, July 29, 2012 /PRNewswire/ -- Paper highlights clinical and immunological activity of IMA901 in renal cell carcinoma (RCC) IMA901 is currently being evaluated in a pivotal phase 3 randomized study in patients with RCC immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of...

2012-06-11 21:34:21

Study shows a cancer therapy for renal cell carcinoma patients may be affected by another anti-cancer drug Research revealed at the Society of Nuclear Medicine's 2012 Annual Meeting explores treatment with a newly developed type of radioimmunotherapy used for treating a resistant form of kidney cancer. The agent is able to hone in on the disease, called clear cell renal carcinoma, and kill the cancer by delivering radiation directly to it. However, the study shows that its effectiveness...

2012-06-03 18:20:47

SOUTH SAN FRANCISCO, Calif., June 4, 2012 /PRNewswire/ -- Onyx Pharmaceuticals (Nasdaq: ONXX) today announced data from the Phase 3 GRID (GIST - Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib. The GRID study met its primary endpoint of progression-free survival (PFS)...

2012-06-03 18:20:41

WAYNE, N.J., June 4, 2012 /PRNewswire/ -- Bayer HealthCare today announced data from the Phase III GRID (GIST - Regorafenib In Progressive Disease) trial evaluating its investigational drug regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib. The GRID study met its primary endpoint of improvement in progression-free survival (PFS) (HR=0.27, p<0.0001).(1) The...

2012-05-16 02:29:59

( ) ( ) ( ) SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the upcoming presentations of data highlighting Nexavar® (sorafenib) tablets, Kyprolis(TM) (proposed trademark for carfilzomib) and regorafenib, a Bayer-owned compound for which Onyx will receive a royalty on global net sales. These presentations will take place at the 48th American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2012, in Chicago,...

2012-05-16 02:29:51

WAYNE, N.J., May 16, 2012 /PRNewswire/ -- Bayer HealthCare announced today that data on Nexavar® (sorafenib) tablets and several of its investigational oncology compounds will be presented in a scientific forum at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, in Chicago, IL. These data, including oral presentations of two Late-Breaking Abstracts on the late-stage compounds regorafenib and radium-223 chloride, reflect Bayer's commitment to oncology...